Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEdesa Biotech Inc

Edesa Biotech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.22 USD 0.20 ( 9.90%)
Last update at 2026-11-11T21:24:00Z
VOLUME
998322
Market Cap
39.72M

Momentum Score

…

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.85
Low
2.31
High
52 Week Price Range
0.72
Low
20.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Edesa Biotech Inc is a clinical-stage biotechnology company developing therapeutic candidates for inflammatory and respiratory diseases. Major long-term growth drivers include advancement of clinical-stage programs through trials and regulatory review, potential partnerships or licensing, and expansion into additional indications if efficacy is shown. The company appears positioned to offer investors exposure to upside from positive clinical readouts while carrying typical early-stage biotech uncertainty.
The most important investment risks are clinical and regulatory failure, limited operating history, and the likely need for additional capital that could dilute shareholders and delay programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.31M
Debt / Equity
0.01
ROE
-122.93%
Net Debt
-10.79M
ROCE
-57.70%
Diluted EPS TTM
-1.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -7.18M -6.17M -8.37M -17.55M -13.34M
Net income -7.19M -6.17M -8.37M -17.55M -13.34M
Selling general administrative 4.24M 4.13M 4.43M 5.04M 5.73M
Selling and marketing expenses - - 0.18M - -
Gross profit -0.12M -0.19M -0.18M -0.12M -0.12M
Reconciled depreciation 0.12M 0.19M 0.18M 0.12M 0.12M
Ebit -7.18M -6.17M -9.22M -18.37M -23.68M
Ebitda -7.07M -5.98M -9.22M -17.59M -13.34M
Depreciation and amortization 0.12M 0.19M 0.18M 0.78M 10.34M
Operating income -7.91M -7.01M -9.22M -18.37M -23.68M
Other operating expenses 7.91M 7.01M 9.22M 17.59M 13.34M
Interest expense - - - 0.82M 0.12M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.00M 0.15M 0.29M 0.06M 0.01M
Net interest income 0.00M 0.15M 0.29M 0.06M 0.01M
Income tax expense 0.00M 0.00M 0.00M 0.00M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 7.79M 7.01M 9.22M 17.59M 13.34M
Cost of revenue 0.12M 0.19M 0.18M 0.12M 0.12M
Total other income expense net 0.73M 0.85M 0.85M 0.82M 10.34M
Net income from continuing ops -7.19M -6.17M -8.37M -17.55M -13.34M
Net income applicable to common shares - - - -17.55M -13.34M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 13.53M 3.81M 8.89M 11.58M 14.58M
Intangible assets 1.98M 2.08M 2.18M 2.28M 2.38M
Other current assets 0.08M 0.37M 0.45M 2.00M 0.95M
Total liab 1.08M 1.83M 1.84M 2.18M 1.53M
Total stockholder equity 12.45M 1.98M 7.05M 9.39M 13.06M
Other current liab 1.08M 1.81M 1.75M 2.12M 1.38M
Common stock 54.52M 47.24M 46.64M 42.47M 34.89M
Capital stock 63.78M 47.24M 46.64M 42.47M 34.89M
Retained earnings -65.91M -58.59M -52.42M -44.04M -26.50M
Other liab - - - 0.04M 0.05M
Other assets - - - 2.00M 14.58M
Cash 10.79M 1.04M 5.36M 7.09M 7.84M
Total current liabilities 1.08M 1.83M 1.82M 2.14M 1.46M
Net debt -10.79M -1.02M -5.27M -7.07M -7.74M
Short term debt - 0.02M 0.07M 0.02M 0.08M
Short long term debt total - 0.02M 0.09M 0.02M 0.10M
Other stockholder equity 14.75M 13.58M 13.04M 11.18M 4.67M
Property plant equipment - - - 0.03M 0.11M
Total current assets 11.51M 1.68M 6.44M 9.09M 12.09M
Net tangible assets - - - 7.11M 10.68M
Net receivables 0.64M 0.27M 0.63M 1.26M 3.30M
Inventory - - - -1.26M -
Accounts payable 1.08M 1.81M - 2.12M 1.38M
Accumulated other comprehensive income -0.17M -0.24M -0.21M -0.21M -0.21M
Non currrent assets other 0.04M 0.04M 0.17M 0.17M -
Non current assets total 2.02M 2.14M 2.45M 2.48M 2.49M
Capital lease obligations 0.00M 0.02M 0.09M 0.02M 0.10M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - - 0.00M -0.01M -0.01M
Change to liabilities - - - 0.88M -0.12M
Total cashflows from investing activities - - - -0.01M -0.01M
Net borrowings 0.00M -0.03M - - -
Total cash from financing activities 17.03M 0.59M 4.83M 11.63M 14.17M
Change to operating activities - - - -0.02M -0.28M
Net income -7.19M -6.17M -8.37M -17.55M -13.34M
Change in cash 9.75M -4.32M -1.73M -0.75M 0.63M
Begin period cash flow 1.04M 5.36M 7.09M 7.84M 7.21M
End period cash flow 10.79M 1.04M 5.36M 7.09M 7.84M
Total cash from operating activities -7.32M -4.89M -6.64M -12.28M -13.66M
Issuance of capital stock 17.60M 0.73M 4.35M 11.96M 12.66M
Depreciation 0.12M 0.19M 0.18M 0.12M 0.12M
Change to account receivables -0.38M 0.36M 0.56M 2027.45M -3.23M
Other cashflows from financing activities 9.88M -0.11M 0.49M -0.33M 1.51M
Change to netincome - - - 2.26M 3.20M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.01M
Change in working capital -0.99M 0.57M 0.31M 2.89M -3.64M
Stock based compensation 0.73M 0.54M 1.25M 2.26M 3.20M
Other non cash items - -0.01M 0.31M 2.38M 3.31M
Free cash flow -7.32M -4.89M -6.64M -12.28M -13.67M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EDSA
Edesa Biotech Inc		 0.20
9.90%		 2.22 - 0.18 130462.29 99.92 140491.25 -1.25
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Edesa Biotech Inc

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

100 Spy Court, Markham, ON, Canada, L3R 5H6

289 800 9600

https://www.edesabiotech.com

17

Name Title Year Born
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Sec. & Director 1971
Dr. Michael J. Brooks M.B.A., Ph.D. Pres 1978
Ms. Kathi Niffenegger CPA, CPA Chief Financial Officer 1957
Mr. Gary Koppenjan VP of Investor Relations & Communications NA
Mr. Rajan Puri Sr. VP of Manufacturing NA
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Secretary & Director 1971
Dr. Michael J. Brooks M.B.A., Ph.D. President 1978
Mr. Stephen L. Lemieux BA, C.P.A., CA, CPA, MMPA Chief Financial Officer 1977
Dr. Michael J. Brooks M.B.A., Ph.D. President 1979
Mr. Peter John Weiler M.B.A, M.Sc. Chief Financial Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…